Next Article in Journal
Investigating Modifiable Factors Associated with Cognitive Decline: Insights from the UK Biobank
Previous Article in Journal
Primary Renal Lymphoma: Report of 32 Cases—A Retrospective Multicenter PLRG Analysis
Previous Article in Special Issue
Expression of Spermine Oxidase Is Associated with Colorectal Carcinogenesis and Prognosis of Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 13
Issue 3
10.3390/biomedicines13030547
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Biomedicines 2022, 10(2), 377.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Leung et al. Preclinical Identification of Sulfasalazine’s Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling. Biomedicines 2022, 10, 377

by
Wai-Hung Leung
1,†,
Jing-Wen Shih
2,3,4,5,†,
Jian-Syun Chen
1,
Ntlotlang Mokgautsi
2,3,
Po-Li Wei
6,7,8 and
Yan-Jiun Huang
6,7,8,*
1
Division of Colon and Rectal Surgery, Department of Surgery, Mackay Memorial Hospital, No. 92, Sec. 2, Zhongshan N. Rd., Taipei 10449, Taiwan
2
Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan
3
Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
4
TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 11031, Taiwan
5
Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
6
Division of Colorectal Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei 110, Taiwan
7
Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
8
Division of General Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei 110, Taiwan
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Biomedicines 2025, 13(3), 547; https://doi.org/10.3390/biomedicines13030547
Submission received: 22 November 2024 / Accepted: 3 December 2024 / Published: 21 February 2025
(This article belongs to the Special Issue Drug Resistance in the Treatment of Colorectal Cancer)
Browse Figure
Versions Notes

Error in Figure

In the original publication, there is a mistake in Figure 11B as published [1]. The images of the colony formation assay are misplaced. The corrected Figure 11 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Leung, W.-H.; Shih, J.-W.; Chen, J.-S.; Mokgautsi, N.; Wei, P.-L.; Huang, Y.-J. Preclinical Identification of Sulfasalazine’s Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling. Biomedicines 2022, 10, 377. [Google Scholar] [CrossRef] [PubMed]
Biomedicines 13 00547 g011
Figure 11. Sulfasalazine (SSZ) treatment reduced the tumorigenic properties of CRC cells and enhanced cisplatin (CDDP) efficacy. (A) SSZ enhanced cisplatin efficacy in both the DLD-1 and HCT116 cell lines. IC50 values are shown. Representative micrographs for the suppressive effects of SSZ on the ability of DLD-1 and HCT116 cells to form (B) colonies and migration, and (C) tumorspheres, as well as showing reduced ALDH activity (cancer stemness marker) in DLD-1 and HCT116 cells. (D) Western blot results show that SSZ and CDDP combined treatment significantly reduced the expression level of KRAS, MMP7, and CD44 on CRC cells compared to their vehicle-treated counterparts. β-actin served as the loading control. ** p < 0.01, *** p < 0.001. Numbers in red represent the relative expression level of the band intensity estimated using ImageJ software.
Figure 11. Sulfasalazine (SSZ) treatment reduced the tumorigenic properties of CRC cells and enhanced cisplatin (CDDP) efficacy. (A) SSZ enhanced cisplatin efficacy in both the DLD-1 and HCT116 cell lines. IC50 values are shown. Representative micrographs for the suppressive effects of SSZ on the ability of DLD-1 and HCT116 cells to form (B) colonies and migration, and (C) tumorspheres, as well as showing reduced ALDH activity (cancer stemness marker) in DLD-1 and HCT116 cells. (D) Western blot results show that SSZ and CDDP combined treatment significantly reduced the expression level of KRAS, MMP7, and CD44 on CRC cells compared to their vehicle-treated counterparts. β-actin served as the loading control. ** p < 0.01, *** p < 0.001. Numbers in red represent the relative expression level of the band intensity estimated using ImageJ software.
Biomedicines 13 00547 g011
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Leung, W.-H.; Shih, J.-W.; Chen, J.-S.; Mokgautsi, N.; Wei, P.-L.; Huang, Y.-J. Correction: Leung et al. Preclinical Identification of Sulfasalazine’s Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling. Biomedicines 2022, 10, 377. Biomedicines 2025, 13, 547. https://doi.org/10.3390/biomedicines13030547

AMA Style

Leung W-H, Shih J-W, Chen J-S, Mokgautsi N, Wei P-L, Huang Y-J. Correction: Leung et al. Preclinical Identification of Sulfasalazine’s Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling. Biomedicines 2022, 10, 377. Biomedicines. 2025; 13(3):547. https://doi.org/10.3390/biomedicines13030547

Chicago/Turabian Style

Leung, Wai-Hung, Jing-Wen Shih, Jian-Syun Chen, Ntlotlang Mokgautsi, Po-Li Wei, and Yan-Jiun Huang. 2025. "Correction: Leung et al. Preclinical Identification of Sulfasalazine’s Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling. Biomedicines 2022, 10, 377" Biomedicines 13, no. 3: 547. https://doi.org/10.3390/biomedicines13030547

APA Style

Leung, W.-H., Shih, J.-W., Chen, J.-S., Mokgautsi, N., Wei, P.-L., & Huang, Y.-J. (2025). Correction: Leung et al. Preclinical Identification of Sulfasalazine’s Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling. Biomedicines 2022, 10, 377. Biomedicines, 13(3), 547. https://doi.org/10.3390/biomedicines13030547

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop